Long term (1-year) effectiveness, safety and tolerability of fremanezumab in migraine: a real-life, prospective, cohort, multicenter study

被引：0

作者：

Egeo, Gabriella ^{[1
]}

Aurilia, Cinzia ^{[1
]}

Orlando, Bianca ^{[1
]}

Fiorentini, Giulia ^{[1
]}

D'Onofrio, Florindo ^{[2
]}

Albanese, Maria ^{[3
]}

Messina, Roberta ^{[4
]}

Di Fiore, Paola ^{[5
]}

Zucco, Maurizio ^{[6
]}

Filippi, Massimo ^{[4
]}

Bartolini, Marco ^{[7
]}

Bono, Francesco ^{[8
]}

Grazzi, Licia ^{[9
]}

Querzani, Pietro ^{[10
]}

Borrello, Laura ^{[11
]}

Doretti, Alberto ^{[12
]}

Gai, Annalisa ^{[13
]}

Proietti, Stefania ^{[14
]}

Bonassi, Stefano ^{[14
,15
]}

Vernieri, Fabrizio ^{[16
]}

Torelli, Paola ^{[17
]}

Barbanti, Piero ^{[1
]}

机构：

[1] IRCCS San Raffaele Roma, Headache & Pain Unit, Rome, Italy

[2] San Giuseppe Moscati Hosp, Neurol Unit, Avellino, Italy

[3] Univ Hosp Tor Vergata, Neurol Unit, Reg Referral Headache Ctr, Rome, Italy

[4] Univ Vita Salute San Raffaele, Sci Inst San Raffaele Hosp, Dept Neurol, Headache Unit, Milan, Italy

[5] ASST Santi Paolo Carlo, Headache Ctr, Milan, Italy

[6] San Camillo Forlanini Hosp, Neurl Unit, Headache Ctr, Rome, Italy

[7] Marche Polytech Univ, Neurol Clin, Ancona, Italy

[8] AOU Mater Domini, Neurol Unit, Ctr Headache & Intracranial Pressure Disorders, Catanzaro, Italy

[9] Headache Ctr Fdn IRCCS Ist Neurol Carlo Besta, Neuroalgol Unit, Milan, Italy

[10] Ravenna Hosp, Headache Ctr, Ravenna, Italy

[11] Frosinone Hosp, Headache Ctr, Frosinone, Italy

[12] IRCCS, Dept Neurol, Lab Neurosci, Ist Auxol Italiano,Stroke Unit, Milan, Italy

[13] Cardinal Massaia Hosp, Headache Ctr, Asti, Italy

[14] IRCCS San Raffaele Roma, Clin & Mol Epidemiol, Rome, Italy

[15] San Raffaele Univ, Rome, Italy

[16] Campus Biomed Univ Hosp, Headache & Neurosonol Unit, Rome, Italy

[17] Univ Parma, Dept Med & Surg, Neurol Unit, Headache Ctr, Parma, Italy

来源：

CEPHALALGIA | 2023年 / 43卷 / 1supp期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

IHC23-PO-2

引用

页码：257 / 258

页数：2

共 50 条

[1] Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real-life study
Zanandrea, Laura
Messina, Roberta
Cetta, Ilaria
Genovese, Federica
Guerrieri, Simone
Vernieri, Fabrizio
Altamura, Claudia
Cevoli, Sabina
Favoni, Valentina
Colombo, Bruno
Filippi, Massimo
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2024,
[2] Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study
Goadsby, P. J.
Monteith, T.
Cohen, J. M.
Yang, R.
[J]. HEADACHE, 2019, 59 : 99 - 99
[3] Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study
Goadsby, Peter
Monteith, Teshamae
Yeung, Paul P.
Cohen, Joshua
Yang, Ronghua
[J]. NEUROLOGY, 2019, 92 (15)
[4] Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Barbanti, Piero
Egeo, Gabriella
Proietti, Stefania
d'Onofrio, Florindo
Aurilia, Cinzia
Finocchi, Cinzia
Di Clemente, Laura
Zucco, Maurizio
Doretti, Alberto
Messina, Stefano
Autunno, Massimo
Ranieri, Angelo
Carnevale, Antonio
Colombo, Bruno
Filippi, Massimo
Tasillo, Miriam
Rinalduzzi, Steno
Querzani, Pietro
Sette, Giuliano
Forino, Lorenzo
Zoroddu, Francesco
Robotti, Micaela
Valenza, Alessandro
Camarda, Cecilia
Borrello, Laura
Aguggia, Marco
Viticchi, Giovanna
Tomino, Carlo
Fiorentini, Giulia
Orlando, Bianca
Bonassi, Stefano
Torelli, Paola
[J]. NEUROLOGY AND THERAPY, 2024, 13 (03) : 611 - 624
[5] Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: a real-life study
Cetta, Ilaria
Messina, Roberta
Zanandrea, Laura
Genovese, Federica
Guerrieri, Simone
Vernieri, Fabrizio
Altamura, Claudia
Cevoli, Sabina
Favoni, Valentina
Colombo, Bruno
Filippi, Massimo
[J]. CEPHALALGIA, 2023, 43 (1supp) : 234 - 235
[6] Safety and tolerability of antiCGRP mAbs in real-life: a multicenter, prospective, observational study on 1635 migraine patients
Egeo, Gabriella
Aurilia, Cinzia
Orlando, Bianca
Fiorentini, Giulia
Torelli, Paola
Finocchi, Cinzia
d'Onofrio, Florindo
d'Onofrio, Luigi
Messina, Stefano
Zucco, Maurizio
Colombo, Bruno
Ranieri, Angelo
Salerno, Antonio
Petolicchio, Barbara
Valenza, Alessandro
Rinalduzzi, Steno
Zoroddu, Francesco
Camarda, Cecilia
Borrello, Laura
Albanese, Maria
Tomino, Carlo
Proietti, Stefania
Bonassi, Stefano
Barbanti, Piero
[J]. CEPHALALGIA, 2023, 43 (1supp) : 240 - 241
[7] Long-Term Safety of Fremanezumab: Results of a 1-Year Study
Ning, Xiaoping
Cohen, Joshua
Bennett, Nathan
Yeung, Paul
Yang, Ronghua
[J]. NEUROLOGY, 2019, 92 (15)
[8] Long-Term Safety of Fremanezumab: Results of a 1-Year Study
Ning, X.
Cohen, J. M.
Bennett, N. L.
Yang, R.
[J]. HEADACHE, 2019, 59 : 47 - 47
[9] Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Vernieri, Fabrizio
Brunelli, Nicoletta
Marcosano, Marilena
Aurilia, Cinzia
Egeo, Gabriella
Lovati, Carlo
Favoni, Valentina
Perrotta, Armando
Maestrini, Ilaria
Rao, Renata
d'Onofrio, Luigi
Finocchi, Cinzia
Aguggia, Marco
Bono, Francesco
Ranieri, Angelo
Albanese, Maria
Di Piero, Vittorio
Cevoli, Sabina
Altamura, Claudia
Barbanti, Piero
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (01) : 224 - 234
[10] Effectiveness And Safety Of Monthly Versus Quarterly Fremanezumab For Migraine Prevention: A Real-Life Pilot Study
Zanandrea, L.
Messina, R.
Cetta, I.
Guerrieri, S.
Altamura, C.
Brunelli, N.
Marcosano, M.
Vernieri, F.
Colombo, B.
Filippi, M.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 692 - 692

← 1 2 3 4 5 →